PDS Biotechnology Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PDSB in the last 30 days.
See all $PDSB insider activity →PDS Biotechnology (PDSB) stock fell 14.92% as shareholders registered 16.5M shares for resale. The company has negative equity (-$3.6M), tight liquidity, and quarterly cash burn of $2.8M. Analysts cite downside risks due to regulatory uncertainty, weak financials, and technical downtrend.
PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.
PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning PDSB (PDS Biotechnology Corp). Coverage has been balanced: 1 bullish, 1 neutral, and 1 bearish.
Recent PDSB coverage spans corporate actions, financial news and technology.
Share overhang likely adds selling pressure, pushing the stock lower.
Potential upside if FDA clears design and trial shows efficacy; risk if delays or negative data.
Near-term momentum is supported by positive Phase 2 clinical readout, but upside is capped by heavy dilution from the PIPE and ongoing financing risk.
The announcement may generate modest buying interest ahead of the data release.
Positive Phase 2 data could lift PDSB stock and attract partnership interest.
AlphAI scores every news story that mentions PDSB with an AI model for sentiment and relevance, and aggregates insider trades from PDS Biotechnology Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
PDS Biotechnology (PDSB) stock fell 14.92% as shareholders registered 16.5M shares for resale. The company has negative equity (-$3.6M), tight liquidity, and quarterly cash burn of $2.8M. Analysts cite downside risks due to regulatory uncertainty, weak financials, and technical downtrend.
3 min readPDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.
2 min readPDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.
6 min readPDS Biotechnology (PDSB) will host a virtual KOL event on Oct 15, 2026, to discuss Phase 2 data for PDS0301 in treating metastatic colorectal cancer with liver metastases. The event features NCI investigator Jonathan M. Hernandez and includes a live Q&A.
1 min readPDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune
2 min readPDS Biotechnology (PDSB) disclosed that Nant Capital, led by Patrick Soon-Shiong, acquired a 19.9% stake in the company. Nant Capital purchased 13,005,334 shares and warrants for $0.2825 per share. The investment includes a milestone closing contingent on PDS0301's Phase 3 trial submission to the FDA, with Nant Capital obligated to invest $10M. Soon-Shiong and James Banaag joined PDS Biotechnology's board.
2 min readPDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.
3 min readPDS Biotechnology (PDSB) retired a $6M debt, paying $4.6M in principal and interest. It raised $11.3M via a PIPE financing led by Nant Capital. Funds will support working capital and clinical trials, including PDS0301's late-stage development. Nant committed additional funding and secured a licensing option for PDS0101. The company added two Nant-affiliated directors to its board.
2 min readPDS Biotechnology (PDSB) repaid a $6M promissory note to Yorkville early on Sep 14, 2026, covering $4.6M in principal and interest. The note, issued Jun 15, 2026, had a 10% annual interest rate and was due Jun 15, 2027. The early redemption reduced debt and interest expenses without penalties, according to the company.
1 min readPDS Biotechnology (PDSB) raised $11.3M in a PIPE deal led by Dr. Patrick Soon-Shiong, who joined the board. The funds will repay debt and advance clinical programs, including PDS0301 for colorectal cancer. Soon-Shiong's NantWorks gained a licensing option for PDS0101.
2 min read
